Alan Lotvin Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 1 week ago
Alan Lotvin has an estimated net worth of at least $21.7 million*, as of Dec. 18, 2024. They own 109,183 shares of CVS stock. They have sold 167,607 shares of CVS stock since 2021, for an estimated $16.7 million.
Alan Lotvin $CVS SEC Form 4 Insider Trading
Alan Lotvin has filed a total of 5 insider trades in $CVS since 2021. Their most recent trade was a sale of 70,398 shares, made on Aug 03, 2022. Their largest trade was a sale of 70,398 shares, made on Aug 03, 2022. We estimate that they now own 109,183 shares of $CVS, worth an estimated $5.0 million.
Insider Trading at $CVS
There have been a total of 41 insider trades reported at $CVS since 2021, with 30,181 shares purchased and 1.0 million shares sold. The most active insider traders in $CVS stock have been Prem S Shah, Daniel P Finke, and Alan Lotvin. The most recent trade was a purchase of 1,000 shares reported by EDWARD J LUDWIG (None), made on May 02, 2024.
History of Insider Stock Trades by Alan Lotvin
Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
---|---|---|---|---|
CVS | Sale | 70,398 | Aug 03, 2022 | Aug. 5, 2022, 4:50 p.m. |
CVS | Sale | 50,501 | Aug 03, 2022 | Aug. 5, 2022, 4:50 p.m. |
CVS | Sale | 22,541 | Aug 04, 2022 | Aug. 5, 2022, 4:50 p.m. |
CVS | Sale | 21,386 | Feb 01, 2022 | Feb. 1, 2022, 8 p.m. |
CVS | Sale | 2,781 | Jun 28, 2021 | June 28, 2021, 8 p.m. |
$CVS Executives and Stock Owners with Insider Trades
-
Prem S Shah, EVP and Co-President of Retail
-
Daniel P Finke, EVP/Pres, Health Care Benefits
-
Alan Lotvin, EVP&President-PharmacyServices
-
Thomas M Moriarty, EVP & General Counsel
-
Troyen A Brennan, EVP and Chief Medical Officer
-
James David Clark, SVP, Cont & Chief Acct Officer
-
Jonathan C Roberts, EVP & Chief Operating Officer
-
Karen S Lynch, President and CEO
-
Prem S Shah, EVP and Pres-Pharm, Consumer W
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.